A. Pembrolizumab B. Atezolizumab C. Ipilimumab D. Nivolumab E. Unsure

A. The combination of nivolumab/ipilimumab is more effective than monotherapy with an immune checkpoint inhibitor. However, if toxicity is a concern, ipilimumab monotherapy is the next best option. B. A targeted therapy regimen, such as encorafenib/binimetinib, is preferred because a BRAF V600 mutation was not detected. C. A single-agent anti–PD-1 regimen is more effective and better tolerated than ipilimumab monotherapy. D. A 3-drug regimen, such as atezolizumab/vemurafenib/cobimetinib, is preferable because RD is young and otherwise healthy. E. Unsure

A. Pembrolizumab B. Nivolumab/ipilimumab C. Dabrafenib/trametinib D. Atezolizumab/vemurafenib/cobimetinib E. Unsure

A. Targeted therapy with a BRAF/MEK combination regimen is preferable because AG's melanoma expresses a BRAF V600E mutation. B. Single-agent anti–PD-1 inhibitors are only a treatment option if AG's tumor expresses PD-L1. C. In the first-line setting, immune checkpoint inhibitor regimens have a higher objective response rate as well as longer median progression-free and overall survivals than targeted therapy regimens. D. Immune checkpoint inhibitor regimens may not be the best option if AG has an autoimmune disease or a history of a transplant. E. Unsure

A. TW can resume treatment today and be re-challenged with single-agent nivolumab. B. TW can resume treatment today and be re-challenged with either single-agent nivolumab or single-agent ipilimumab. C. TW can be re-challenged with single-agent nivolumab, but his current prednisone dose exceeds the threshold for treatment today. D. TW can be re-challenged with either single-agent nivolumab or single-agent ipilimumab, but his current prednisone dose exceeds the threshold for treatment today. E. TW cannot receive further immunotherapy because he had grade 3 transaminitis. F. Unsure